Kelly P. Burke

Kelly P. Burke

Auto-generated profile, based on publicly available information

Kelly P. Burke

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Cancer Cell
Verified
Journal Article
Closed access
DBDavid A. Braun
David A. Braun
KSKelly Street
Kelly Street
KBKelly P. Burke
Kelly P. Burke
DCDavid L. Cookmeyer
David L. Cookmeyer
TDThomas Denize
Thomas Denize
CWCatherine J. Wu
Catherine J. Wu

26 January 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
JTJun Tian
Jun Tian
JCJonathan H. Chen
Jonathan H. Chen
SCSherry X. Chao
Sherry X. Chao
KPKarin Pelka
Karin Pelka
MGMarios Giannakis
Marios Giannakis
RCRyan B. Corcoran
Ryan B. Corcoran
While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical efficacy in BRAFV600E colorectal cancer (CRC), response rates remain low and lack durability. Preclinical data suggest that BRAF/MAPK pathway inhibition may augment the tumor immune response. We performed a proof-of-concept single-arm phase 2 clinical trial of combined PD-1, BRAF and MEK inhibition with sparatlizumab (PDR001), dabrafenib and trametinib in 37 patients with BRAFV600E CRC. The primary end point was overall response rate, and the secondary end points were progression-free survival, disease control rate, duration of response and overall survival. The study met its primary end point with a confirmed response rate (24.3% in all patients; 25% in microsatellite stable patients) and durability that were favorable relative to historical controls of BRAF-targeted combinations alone. Single-cell RNA sequencing of 23 paired pretreatment and day 15 on-treatment tumor biopsies revealed greater induction of tumor cell-intrinsic immune programs and more complete MAPK inhibition in patients with better clinical outcome. Immune program induction in matched patient-derived organoids correlated with the degree of MAPK inhibition. These data suggest a potential tumor cell-intrinsic mechanism of cooperativity between MAPK inhibition and immune response, warranting further clinical evaluation of optimized targeted and immune combinations in CRC. ClinicalTrials.gov registration: NCT03668431.

4 March 2021 in Nature Medicine
Verified
Journal Article
Open access
PDF file
MHMeng Xiao He
Meng Xiao He
MCMichael S. Cuoco
Michael S. Cuoco
JCJett Crowdis
Jett Crowdis
ABAlice Bosma-Moody
Alice Bosma-Moody
ZZZhenwei Zhang
Zhenwei Zhang
EAEliezer Van Allen
Eliezer Van Allen
Metastatic castration-resistant prostate cancer is typically lethal, exhibiting intrinsic or acquired resistance to second-generation androgen-targeting therapies and minimal response to immune checkpoint inhibitors1. Cellular programs driving resistance in both cancer and immune cells remain poorly understood. We present single-cell transcriptomes from 14 patients with advanced prostate cancer, spanning all common metastatic sites. Irrespective of treatment exposure, adenocarcinoma cells pervasively coexpressed multiple androgen receptor isoforms, including truncated isoforms hypothesized to mediate resistance to androgen-targeting therapies2,3. Resistance to enzalutamide was associated with cancer cell–intrinsic epithelial–mesenchymal transition and transforming growth factor-β signaling. Small cell carcinoma cells exhibited divergent expression programs driven by transcriptional regulators promoting lineage plasticity and HOXB5, HOXB6 and NR1D2 (refs.4–6). Additionally, a subset of patients had high expression of dysfunction markers on cytotoxic CD8+T cells undergoing clonal expansion following enzalutamide treatment. Collectively, the transcriptional characterization of cancer and immune cells from human metastatic castration-resistant prostate cancer provides a basis for the development of therapeutic approaches complementing androgen signaling inhibition.

13 February 2024 in Immunity
Verified
Journal Article
Closed access
KBKelly P. Burke
Kelly P. Burke
ACApoorvi Chaudhri
Apoorvi Chaudhri
GFGordon J. Freeman
Gordon J. Freeman
ASArlene H. Sharpe
Arlene H. Sharpe

2 March 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
KPKristen E. Pauken
Kristen E. Pauken
OSOsmaan Shahid
Osmaan Shahid
KLKaitlyn A. Lagattuta
Kaitlyn A. Lagattuta
KMKelly Mahuron
Kelly Mahuron
JLJacob Luber
Jacob Luber
MSMeromit Singer
Meromit Singer
The ability to monitor anti-tumor CD8+ T cell responses in the blood has tremendous therapeutic potential. Here, we used paired single-cell RNA and TCR sequencing to detect and characterize “tumor-matching” (TM) CD8+ T cells in the blood of mice with MC38 tumors or melanoma patients using the TCR as a molecular barcode. TM cells showed increased activation compared with nonmatching T cells in blood and were less exhausted than matching cells in tumors. Importantly, PD-1, which has been used to identify putative circulating anti-tumor CD8+ T cells, showed poor sensitivity for identifying TM cells. By leveraging the transcriptome, we identified candidate cell surface markers for TM cells in mice and patients and validated NKG2D, CD39, and CX3CR1 in mice. These data show that the TCR can be used to identify tumor-relevant cells for characterization, reveal unique transcriptional properties of TM cells, and develop marker panels for tracking and analysis of these cells.

15 April 2022 in Science Advances
Verified
Journal Article
Open access
MHMohamed S. Hasim
Mohamed S. Hasim
MMMarie Marotel
Marie Marotel
JHJonathan J. Hodgins
Jonathan J. Hodgins
EVElisabetta Vulpis
Elisabetta Vulpis
OMOlivia J. Makinson
Olivia J. Makinson
MAMichele Ardolino
Michele Ardolino
Trogocytosis modulates immune responses, with still unclear underlying molecular mechanisms. Using leukemia mouse models, we found that lymphocytes perform trogocytosis at high rates with tumor cells. While performing trogocytosis, both Natural Killer (NK) and CD8 + T cells acquire the checkpoint receptor PD-1 from leukemia cells. In vitro and in vivo investigation revealed that PD-1 on the surface of NK cells, rather than being endogenously expressed, was derived entirely from leukemia cells in a SLAM receptor–dependent fashion. PD-1 acquired via trogocytosis actively suppressed NK cell antitumor immunity. PD-1 trogocytosis was corroborated in patients with clonal plasma cell disorders, where NK cells that stained for PD-1 also stained for tumor cell markers. Our results, in addition to shedding light on a previously unappreciated mechanism underlying the presence of PD-1 on NK and cytotoxic T cells, reveal the immunoregulatory effect of membrane transfer occurring when immune cells contact tumor cells.